Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (101-110 of 209) with videos related to

Pageof 21
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.
Lung Cancer (Auckland, N.Z.)|August 18, 2025
Alectinib Efficacy Post-Brigatinib Against Advanced <i>ALK</i>+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)Renaud Descourt, Florian Guisier, Maurice Pérol, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
Medicine|February 4, 2020
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinomaOlivier Bylicki, Florian Guisier, Isabelle Monnet, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)Isabelle Martel-Lafay, Isabelle Monnet, Audrey Lardy-Cleaud, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patientsPerrine Créquit, Anne-Marie Ruppert, Nathalie Rozensztajn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2013
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089)Achim Rittmeyer, Vera Gorbunova, Anders Vikström, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 18, 2012
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesisMariette Baud, Salvatore Strano, Agnes Dechartres, et al.
Bulletin Du Cancer|September 12, 2025
[Subcutaneous versus intravenous routes in oncology: Preferences and impacts for patients and healthcare professionals]Sarah Mir, Katia Desroziers, Sarah Saget, et al.
Pageof 21

Showing results (101-110 of 209) with videos related to

Sort By:
Pageof 21
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2012
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across EuropeSilke Walleser, Joshua Ray, Helge Bischoff, et al.
Lung Cancer (Auckland, N.Z.)|August 18, 2025
Alectinib Efficacy Post-Brigatinib Against Advanced <i>ALK</i>+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)Renaud Descourt, Florian Guisier, Maurice Pérol, et al.
Respiratory Medicine and Research|February 21, 2026
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progressionPaul Lajoinie, Vincent Fallet, Marie Wislez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
Medicine|February 4, 2020
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinomaOlivier Bylicki, Florian Guisier, Isabelle Monnet, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)Isabelle Martel-Lafay, Isabelle Monnet, Audrey Lardy-Cleaud, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patientsPerrine Créquit, Anne-Marie Ruppert, Nathalie Rozensztajn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2013
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089)Achim Rittmeyer, Vera Gorbunova, Anders Vikström, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 18, 2012
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesisMariette Baud, Salvatore Strano, Agnes Dechartres, et al.
Bulletin Du Cancer|September 12, 2025
[Subcutaneous versus intravenous routes in oncology: Preferences and impacts for patients and healthcare professionals]Sarah Mir, Katia Desroziers, Sarah Saget, et al.
Pageof 21